Following genetic diagnosis, the proband was transitioned from insulin to glimepiride, achieving optimal glycemic control.<h4>Conclusions</h4>This study identifies a <i>HNF1A</i> whole-gene deletion in a Chinese family with MODY, confirming the effectiveness of sulfonylureas for HNF1A-MODY management. The gene discussed is INS; the disease is MODY.